Saroja Pharma Industries India Ltd

Saroja Pharma In's historical performance shows growth in net sales and profits from Mar'24 to Mar'25, with net sales rising to 53.73 Cr and profit after tax increasing to 1.03 Cr, despite significant increases in raw material costs and total liabilities. The company also improved its operating profit and earnings per share during this period.

As of 11-Nov, Saroja Pharma Industries India Ltd's stock price is declining at 41.25, down 4.4%, and has underperformed its sector significantly. The stock is trading below all major moving averages, with a notable drop in investor participation and a year-to-date decline of 31.25%, indicating ongoing challenges for the company.

As of 20-Oct, Saroja Pharma Industries India Ltd's stock price is 43.60, down 4.39%, and has underperformed its sector by 5.07%. Despite a significant increase in investor participation, the stock has declined 7.43% over the past week and 27.33% year-to-date, contrasting sharply with the Sensex's positive performance.

As of October 6, 2025, Saroja Pharma is considered overvalued with a PE ratio of 17.45 and has underperformed the Sensex with a return of -22.06%, making it a less attractive investment at its current price of 44.70.

As of October 3, 2025, Saroja Pharma is fairly valued at a price of 42.80, with a PE ratio of 16.71 and a PEG ratio of 0.98, despite underperforming the Sensex with a year-to-date return of -28.67%.

As of 24-Sep, Saroja Pharma Industries India Ltd's stock price is flat at 46.00, with a year-to-date decline of 23.33%. Despite recent outperformance against its sector, the stock has underperformed compared to the Sensex, indicating declining investor interest and mixed technical signals.

As of 23-Sep, Saroja Pharma Industries India Ltd's stock price is flat at 46.00, with a recent underperformance reflected in a -2.23% return over the past week and a -17.12% return over the past month. The stock is currently above longer-term moving averages but below shorter ones, indicating mixed performance and declining investor interest.

As of 22-Sep, Saroja Pharma Industries India Ltd's stock price is 46.00, up 1.88% today, but has declined 17.12% over the past month. Despite outperforming its sector today, it has underperformed the Sensex year-to-date, indicating challenges in regaining investor confidence.

As of 19-Sep, Saroja Pharma Industries India Ltd's stock price is at 45.15, down 4.85%, and has underperformed its sector by 5.12%. The stock has declined 24.75% year-to-date, contrasting sharply with the Sensex's 7.11% increase, indicating significant investor concerns.

As of 18-Sep, Saroja Pharma Industries India Ltd is priced at 47.45, reflecting a recent increase but significant underperformance over the past year with a decline of 20.05%. The stock is currently below its short-term moving averages and has seen a notable decrease in investor participation, contrasting sharply with the overall market's upward trend.

As of 17-Sep, Saroja Pharma Industries India Ltd's stock price is flat at 47.05, with no change in percentage terms (0.00%). The stock has seen a significant year-to-date decline of 21.58%, underperforming compared to the broader market, despite a recent monthly gain of 20.64%.

As of 16-Sep, Saroja Pharma Industries India Ltd's stock price is flat at 47.05, with no change (0.00%). The stock has underperformed its sector and the broader market, showing a year-to-date decline of 21.58%, despite a positive return of 20.64% over the past month.

As of 15-Sep, Saroja Pharma Industries India Ltd's stock price remains unchanged at 47.05. Despite a recent positive monthly return of 20.64%, the stock has underperformed year-to-date and over the past year, raising concerns about declining investor interest and mixed performance signals.

As of 12-Sep, Saroja Pharma Industries India Ltd's stock price is declining at 47.05, down 4.47%, and has underperformed its sector. Despite increased investor participation, the stock has significantly lagged behind the Sensex, which has gained 6.21% year-to-date, indicating a lack of investor confidence in the company's prospects.

As of 11-Sep, Saroja Pharma Industries India Ltd's stock price remains unchanged at 49.25, underperforming its sector today and experiencing a significant decline of 26.87% over the past week. Despite a positive return of 25.48% over the past month, the stock has faced challenges, reflected in its year-to-date decline of 17.92% compared to the Sensex's gain of 5.75%.

As of 10-Sep, Saroja Pharma Industries India Ltd's stock price is at 49.25, unchanged, and has underperformed its sector by 0.38%. Despite a significant increase in delivery volume, the stock has declined 0.51% over the past week and 17.92% year-to-date, contrasting with the broader market's gains.

As of 09-Sep, Saroja Pharma Industries India Ltd's stock price remains unchanged at 49.25, with a recent positive trend over the past week and month, outperforming the Sensex. However, it has a year-to-date decline of 17.92%, indicating ongoing challenges despite recent gains.

As of 08-Sep, Saroja Pharma Industries India Ltd's stock price is at 49.25, down 4.83%, with a significant drop in investor participation. Despite a 2.50% gain over the past week, the stock has underperformed year-to-date by 17.92% compared to the Sensex's 4.77% gain.

As of September 5, 2025, Saroja Pharma is fairly valued with a PE ratio of 20.20, outperforming the Sensex and positioned competitively against peers like Dr. Reddy's Labs, while significantly lower than Sun Pharma and Divi's Lab.